Tuesday, April 25, 2017
Anaconda BioMed, a pre-clinical stage medical device company focused on the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna Medical to develop, test and manufacture its ANCD BRAIN device as the product advances towards regulatory and clinical phases.
"This is another important step for Anaconda Biomed to secure our path to commercialize our ANCD BRAIN, the 3rd generation thrombectomy device," said the CEO of Anaconda BioMed, Dr. Ofir Arad.
Under the terms of the agreement, Creganna Medical will support Anaconda Biomed in the final stages of its product development process including manufacturing of the ANCD BRAIN medical device for the company's forthcoming clinical trial to obtain CE approval in the EU.
"Our existing partnership with Creganna Medical over the past 18 months, throughout our R&D phase, has resulted in the design of a top-class device. We are pleased to confirm that we are extending our current engagement for the next phase of our product's development. The Creganna Medical team have proven to be enthusiastic, professional and committed, consistently delivering innovative solutions and unparalleled product quality. Our existing partnership is a strong foothold for our next regulatory phase of validation and verification of the ANCD BRAIN device," said the COO of Anaconda BioMed, Dr. Inyaki Galve.
"We are looking forward to continued support of our customer, Anaconda BioMed., to further develop and manufacture their innovative neurovascular device," said Pat Duane, SVP & GM, Creganna Medical. "The ANCD BRAIN device requires a complex manufacturing process and our expertise in advanced device assembly coupled with our vertically integrated supply chain makes us an attractive partner. In addition, we are skilled in supporting emerging companies as their product development process matures, providing scaling support for clinical trial phases and product launch. We are delighted to have been chosen by Anaconda BioMed to assist the development of their innovative medical device to advance Acute Ischemic Stroke treatment, a condition that affects over 15 million people worldwide each year."
